A key strategy for targeting EndMT involves the development of antibody‒drug conjugates that inhibit microtubule protein polymerisation and target TGF‐β signalling, thereby delaying the progression of diseases such as tumours.225, 226, 227, 228, 229, 230, 231. This evidence concerns the gene TGFB1 and neoplasm.